美国食品和药物管理局批准诺瓦瓦克斯的COVID-19疫苗用于高危成年人,但有条件. FDA approves Novavax's COVID-19 vaccine for at-risk adults, with conditions.

林业发展局批准了Novavax的COVID-19疫苗Nuvaxovid,对象是65岁及65岁以上的成年人和12岁及12岁以上的人,其基本条件增加了他们遭受严重后果的风险。 The FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older and those 12 and older with underlying conditions that increase their risk of severe outcomes. 批准要求Novavax对疫苗和心脏状况之间可能的联系进行更多的研究。 The approval requires Novavax to conduct additional studies on potential links between the vaccine and heart conditions. 尽管存在种种限制,但批准被视为Novavax的胜利,并促使其商业伙伴Sanofi支付1.75亿美元。 Despite restrictions, the approval is seen as a win for Novavax and triggers a $175 million payment from Sanofi, its commercial partner.